Online inquiry

IVTScrip™ mRNA-Anti-Aβ15-42, ACC-001(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1434MR)

This product GTTS-WQ1434MR is a type of mRNA modified with N1-Methylpseudo-UTP, which ecodes the monoclonal antibody that targets Aβ15-42 gene. The antibody can be applied in Alzheimer's disease (AD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Corynebacterium diphtheriae; Homo sapiens
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Aβ15-42, ACC-001(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ1434MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ813MR IVTScrip™ mRNA-Anti-LRRC15, ABBV-085(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABBV-085
GTTS-WQ15665MR IVTScrip™ mRNA-Anti-EPCAM, VB6-845(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA VB6-845
GTTS-WQ9487MR IVTScrip™ mRNA-Anti-C5AR1, IPH-5401(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IPH-5401
GTTS-WQ6867MR IVTScrip™ mRNA-Anti-KLKB1, DX-2930(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA DX-2930
GTTS-WQ9124MR IVTScrip™ mRNA-Anti-MUC1, IMGN242(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMGN242
GTTS-WQ2483MR IVTScrip™ mRNA-Anti-CD3E&FOLH1, AMG 212(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 212
GTTS-WQ7296MR IVTScrip™ mRNA-Anti-CSF1R, FPA-008(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA FPA-008
GTTS-WQ9277MR IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IMMU-132
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW